Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

CAR (chimeric antigen receptor) anatomy

In one sentence

A chimeric antigen receptor connects an external antigen-binding region to internal signaling machinery in an engineered immune cell.

The intuition

A sensor attached to a living responder is different from a free-floating drug. The chimeric antigen receptor (CAR) binds a target and can trigger cellular activity. Its behavior still depends on the cell, the target and the surrounding tissue.

How it works

A typical CAR contains a binding region outside the cell, a hinge and membrane-spanning region, and signaling regions inside. Many designs use antibody-derived binding elements. Common signaling designs combine CD3-zeta with a costimulatory region, such as CD28 or 4-1BB.

A conventional surface-antigen CAR can recognize an accessible antigen without a peptide being presented by human leukocyte antigen (HLA). This differs from a conventional T-cell receptor, which reads peptide and HLA together. Specialized designs can depart from these common formats.

Antigen density, geometry, binding strength and cell state influence response. Engineering instructions must first yield a correctly expressed receptor. Receptor presence then needs to be distinguished from binding, signaling, killing and durable benefit.

External antigen-binding region Hinge and membrane-spanning region Internal signaling regions Cell response depends on state and environment Antigen on cancer or healthy tissue

The same intended antigen can trigger useful recognition or healthy-tissue injury.

Why it matters in cancer

A CAR may avoid one presentation dependency while creating target-distribution and healthy-tissue risks. A target on normal tissue can cause on-target, off-tumor injury: the intended binding occurs in an unwanted place.

Worked example

A fictional CAR recognizes target X. Some cancer cells lack X, while a healthy tissue expresses it. Increasing receptor affinity may change recognition thresholds for both. “Stronger binding” alone cannot decide whether the finished therapy has a better therapeutic window.

Common confusions

  • A CAR is a protein, not the engineered cell or the delivered gene.
  • HLA-independent recognition does not guarantee safe tumor coverage.
  • Delivery targeting and cancer targeting are separate jobs.

Sources and scope

Source check: October 8, 2026. This is a mechanism explanation, not a treatment recommendation. Expert and learner review remain pending.

Used in